Otto LAM

Title : Randomized double-blind placebo-controlled crossover trial with pyridostigmine in spinal muscular atrophy types 2-4 - Stam_2023_Brain.Commun_5_fcac324

Author(s) : Stam M , Wijngaarde CA , Bartels B , Asselman FL , Otto LAM , Habets LE , van Eijk RPA , Middelkoop BM , Goedee HS , de Groot JF , Roes KCB , Schoenmakers M , Nieuwenhuis EES , Cuppen I , van den Berg LH , Wadman RI , van der Pol WL

Ref : Brain Commun , 5 :fcac324 , 2023

Abstract :

PubMedSearch : Stam_2023_Brain.Commun_5_fcac324

PubMedID: 36632180

Title : Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial) - Stam_2018_BMJ.Open_8_e019932

Author(s) : Stam M , Wadman RI , Wijngaarde CA , Bartels B , Asselman FL , Otto LAM , Goedee HS , Habets LE , de Groot JF , Schoenmakers M , Cuppen I , van den Berg LH , van der Pol WL

Ref : BMJ Open , 8 :e019932 , 2018

Abstract :

PubMedSearch : Stam_2018_BMJ.Open_8_e019932

PubMedID: 30061431

Otto LAM

References (2)

1. Randomized double-blind placebo-controlled crossover trial with pyridostigmine in spinal muscular atrophy types 2-4 - Stam_2023_Brain.Commun_5_fcac324

2. Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial) - Stam_2018_BMJ.Open_8_e019932